Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
AUDs are difficult to treat, and relapse rates are high, with an estimated 80% of individuals
with AUDs returning to alcohol use after completing addictions treatment. Novel treatment
approaches are needed to enhance long term sobriety. The investigator's research team has
been investigating the use of acamprosate to prevent relapse to alcohol use. Unfortunately
despite being FDA approved and endorsed by the American Psychiatric Association only 10% of
patients treated for AUD are prescribed acamprosate or other antidipsotropic medications. The
number is higher for patients treated in programs affiliated with Mayo Clinic Addiction
Services (approximately 20%) but is way less than expected. The most common reasons behind
these low numbers are the understanding that not every patient benefits from the use of
specific medication and the lack of biomarkers predictive of response. The purpose of this
project is to identify such biomarkers by discovery of genomic and metabolomic markers
associated with response to acamprosate treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)